Carcinoid Syndrome Pipeline Analysis Demonstrates Novel 3+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

 Breaking News
  • No posts were found

Carcinoid Syndrome Pipeline Analysis Demonstrates Novel 3+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

March 15
09:21 2023

DelveInsight’s, “Carcinoid Syndrome Pipeline Insight 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the Carcinoid Syndrome pipeline drug profiles, including Carcinoid Syndrome clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Carcinoid Syndrome Emerging drugs, the Carcinoid Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Carcinoid Syndrome pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Carcinoid Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Carcinoid Syndrome clinical trials studies, Carcinoid Syndrome NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Carcinoid Syndrome Pipeline Report

 

  • Over 3+ Carcinoid Syndrome companies are evaluating 3+ Carcinoid Syndrome pipeline therapies in various stages of development, and their anticipated acceptance in the Carcinoid Syndrome market would significantly increase market revenue.

 

  • The leading Carcinoid Syndrome Companies include Crinetics Pharmaceuticals, Aquestive Therapeutics, Entrinsic Biosciences, and others.

 

  • Promising Carcinoid Syndrome Pipeline Therapies include Telotristat Etiprate, Lanreotide, Octreotide LAR Depot, Xermelo, and others.

 

  • The Carcinoid Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Syndrome R&D. The Carcinoid Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Carcinoid Syndrome.

 

Request a sample and discover the recent breakthroughs happening in the Carcinoid Syndrome Pipeline landscape @ Carcinoid Syndrome Pipeline Outlook Report

 

Carcinoid Syndrome Overview

Carcinoid syndrome is a disease consisting of a combination of symptoms, physical manifestations, and abnormal laboratory findings. It is also known as carcinoid apudoma, carcinoid cancer, carcinoid disease, and functioning argentaffinoma. The signs and symptoms of carcinoid syndrome depend on which chemicals the carcinoid tumor secretes into your bloodstream. Carcinoid syndrome is caused by a carcinoid tumor that secretes serotonin or other chemicals into your bloodstream.

 

Recent Developmental Activities in the Carcinoid Syndrome Treatment Landscape

 

  • In May 2021, Crinetics Pharmaceuticals announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. Crinetics mentions that it had plans to advance paltusotine into a Phase II trial to treat carcinoid syndrome associated with neuroendocrine tumors.

 

  • Octreotide (Sandostatin) injections are the backbone for symptomatic management of Carcinoid Syndrome. Xermelo (telotriastat ethyl) tablets combined with somatostatin analog (SSA) therapy is FDA approved for treating Carcinoid Syndrome adults.

  

For further information, refer to the detailed Carcinoid Syndrome Drugs Launch, Carcinoid Syndrome Developmental Activities, and Carcinoid Syndrome News, click here for Carcinoid Syndrome Ongoing Clinical Trial Analysis

 

Carcinoid Syndrome Emerging Drugs Profile

 

  • Paltusotine: Crinetics Pharmaceuticals

Paltusotine (CRN 00808) is an oral non-peptide somatostatin receptor 2 agonist. The drug is in Phase I clinical studies for the treatment of acromegaly and in Phase I clinical studies for the treatment of carcinoid syndrome. Crinetics plans to advance paltusotine into a Phase II trial to treat carcinoid syndrome associated with NETs in 2022.

 

  • AQST-305-SF: Aquestive Therapeutics

AQST-305-SF is a sublingual film with octreotide formulation. The drug is in Phase I clinical studies for the treatment of carcinoid syndrome and acromegaly.

 

Carcinoid Syndrome Pipeline Therapeutics Assessment

There are approx. 3+ key companies which are developing the therapies for Carcinoid Syndrome. The companies which have their Carcinoid Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Crinetics Pharmaceuticals.

 

Find out more about the Carcinoid Syndrome Pipeline Segmentation, Therapeutics Assessment, and Carcinoid Syndrome Emerging Drugs @ Carcinoid Syndrome Treatment Landscape

 

Scope of the Carcinoid Syndrome Pipeline Report

 

  • Coverage- Global

 

  • Carcinoid Syndrome Companies- Crinetics Pharmaceuticals, Aquestive Therapeutics, Entrinsic Biosciences, and others.

 

  • Carcinoid Syndrome Pipeline Therapies- Telotristat Etiprate, Lanreotide, Octreotide LAR Depot, Xermelo, and others.

 

  • Carcinoid Syndrome Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Carcinoid Syndrome Pipeline Companies and Therapies, click here @ Carcinoid Syndrome Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Carcinoid Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Carcinoid Syndrome – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Eenterade: Entrinsic Biosciences
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Paltusotine: Crinetics Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Carcinoid Syndrome Key Companies
  21. Carcinoid Syndrome Key Products
  22. Carcinoid Syndrome- Unmet Needs
  23. Carcinoid Syndrome- Market Drivers and Barriers
  24. Carcinoid Syndrome- Future Perspectives and Conclusion
  25. Carcinoid Syndrome Analyst Views
  26. Appendix

 

Got Queries? Find out the related information on Carcinoid Syndrome Mergers and acquisitions, Carcinoid Syndrome Licensing Activities @ Carcinoid Syndrome Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/